Recursion Pharmaceuticals Raises $200M in Stock Offering

Event summary

Recursion Pharmaceuticals priced a $200 million underwritten offering of 61,540,000 shares of Class A common stock at $3.25 per share.
The offering is expected to close on or about October 16, 2026, subject to customary closing conditions.
Leerink Partners, Goldman Sachs, Morgan Stanley, and Evercore Group acted as joint bookrunning managers.
The financing included participation from leading healthcare and institutional investors, including Janus Henderson Investors and ARK Invest.

The big picture

Recursion's $200 million stock offering underscores the growing investor interest in AI-enabled drug discovery platforms. The financing comes at a time when biotech companies are increasingly leveraging AI to accelerate drug development and reduce costs. The participation of prominent healthcare investors highlights the strategic importance of Recursion's platform in decoding biology for various therapeutic areas. The success of this offering will be closely watched as an indicator of the market's appetite for AI-driven biotech innovations.

What we're watching

Capital Deployment: How Recursion will allocate the $200 million proceeds to advance its AI-enabled drug discovery platform and pipeline.
Market Valuation: Whether the offering at $3.25 per share reflects investor confidence in Recursion's long-term strategy and execution.
Competitive Positioning: The pace at which Recursion can differentiate itself in the crowded AI-driven drug discovery space.